Pharmacokinetic, Efficacy and Safety of BT524 in Patients With Congenital Fibrinogen Deficiency

NCT02065882 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

67

Enrollment

INDUSTRY

Sponsor class

Conditions

Congenital Afibrinogenemia
Congenital Hypofibrinogenemia

Interventions

DRUG: BT524 (Part I)
DRUG: BT524 (Part II)

Sponsor

Biotest

Collaborators

[object Object]
[object Object]
[object Object]